BALTIMORE - A federal judge in Maryland on March 26 dismissed a lead plaintiff's securities class action complaint against a drug company and others, ruling that the lead plaintiff failed to properly plead scienter in making his federal securities law claims (In re Human Genome Sciences Inc. Securities Litigation, No. 11-03231, D. Md.)....(read more)![]()
↧